Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 21427404.
- Also identified by DOI 10.1093/cid/cir029.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The impact of cotrimoxazole (CTX) on growth and/or anemia was investigated in 541 human immunodeficiency virus-infected, antiretroviral therapy-naive Zambian children enrolled in the Children with HIV Antibiotic Prophylaxis trial. Compared with children randomized to receive placebo, children randomized to receive CTX had slower decreases in weight-for-age (P=.04) and height-for-age (P=.01), and greater increase in hemoglobin level (P=.01). These findings argue for expanded early CTX use.
Medical subject headings
- Anemia
- Antimalarials
- Child Development
- HIV Infections
- Malaria
- Trimethoprim, Sulfamethoxazole Drug Combination